13 results
Signaling Mechanism of PD-1 and PD-L1 and Inhibition of PD-1 Signaling in Microsatellite-Instability–High Cancers. MHC1 denotes
Pathophysiology #Honc #Pharm ... #PD1 #PDL1 #Inhibition ... MicrosatelliteInstability #NEJM
PCI in Acute MI with Cardiogenic Shock. #EBM #Cardiology #CULPRITSHOCK #PCI #VisualAbstract #NEJM
PCI in Acute MI ... #EBM #Cardiology ... #CULPRITSHOCK #PCI ... VisualAbstract #NEJM
Major Clinical Trials and Evidence Summary for Transfusion Thresholds in Critical Care

TRICC - NEJM 1999 -
Care TRICC - NEJM ... - ICU FOCUS - NEJM ... UGIB TRISS - NEJM ... unnecessary and cause harm ... /vmoitra) #EBM
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction (VALIDATE-SWEDEHEART) #EBM #Cardiology #VALIDATE #SWEDEHEART #Bivalirudin #Heparin #PCI #VisualAbstract
VALIDATE-SWEDEHEART) #EBM ... Bivalirudin #Heparin #PCI ... VisualAbstract #NEJM
PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock - Event Rates of the
PCI Strategies in ... #EBM #Cardiology ... #CULPRITSHOCK #PCI ... #cardiogenic #NEJM
Pembrolizumab Response Rate by Tumor Type #EBM #Honc #Pharm #Pembrolizumab #Response #TumorType #Colorectal #Endometrial #Biliary #NEJM
by Tumor Type #EBM ... #Honc #Pharm #Pembrolizumab ... Endometrial #Biliary #NEJM
Effect of Tolvaptan on the Estimated Glomerular Filtration Rate (GFR). #EBM #Nephro #Pharm #Tolvaptam #PCKD #PolyCysticKidneyDisease
#EBM #Nephro #Pharm ... PolyCysticKidneyDisease #NEJM
Event Rates of the Primary End Point and Its Components at 30 Days #EBM #Cardiology #CULPRIT-SHOCK
Components at 30 Days #EBM ... #CULPRITSHOCK #PCI ... #cardiogenic #NEJM
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (RE-DUAL PCI trial) - Shown is
Dabigatran after PCI ... Fibrillation (RE-DUAL PCI ... warfarin (Panel A) #EBM ... TripleTherapy #PCI ... AtrialFibrillation #NEJM
Rate of Survival and the Risk of Death at 90 Days, According to Subgroup #EBM #PCC
According to Subgroup #EBM ... #PCC #ADRENAL # ... #SepticShock #NEJM